This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rizos, E. Articles by Mikhailidis, D. P. Search for Related Content PubMed PubMed Citation Articles by Rizos, E. Articles by Mikhailidis, D. P. Social Bookmarking                         What's this?

The Combination of Nebivolol plus Pravastatin is Associated with a More Beneficial Metabolic Profile Compared to that of Atenolol plus Pravastatin in Hypertensive Patients with Dyslipidemia: A Pilot Study

Department of Internal Medicine, Medical School University of Ioannina, London, UK

Eleni Bairaktari, PhD

Laboratory of Chemistry University Hospital of loannina, London, UK

Angeliki Kostoula, MD

Laboratory of Microbiology, University Hospital of loannina, London, UK

George Hasiotis, PhD

Laboratory of Chemistry University Hospital of loannina, London, UK

Apostolos Achimastos, MD

Department of Internal Medicine, Medical School, University of Athens, London, UK

Emanuel Ganotakis, MD

Department of Internal Medicine, University Hospital of Crete, London, UK

Moses Elisaf, MD, FRSH, FACA

Department of Internal Medicine, Medical School University of Ioannina, London, UK

D. P. Mikhailidis, BSc, MSc, MD, FRSH, FACA, FRCPath

Department of Clinical Biochemistry, Royal Free Hospital, London, UK

Nebivolol, a selective ß₁-lipophilic blocker, achieves blood pressure control by modulating nitric oxide release in addition to b-blockade. This dual mechanism of action could result in minimum interference with lipid metabolism compared to atenolol, a classic (ß₁-selective blocker. Hypertensive patients commonly exhibit lipid abnormalities and frequently require statins in combination with the anti-hypertensive therapy. We conducted this trial in order to clarify the effect on the metabolic profile of ß-blocker therapy with atenolol or nebivolol alone, or in conjunction with pravastatin. Thirty hypertensive hyperlipidemic men and women (total cholesterol >240 mg/dL [6.2 mmol/L], low-density lipoprotein cholesterol >190 mg/dL [4.9 mmol/L], triglycerides <500 mg/dL [5.6 mmol/L]) were separated in two groups. One group consisted of 15 subjects on atenolol therapy (50 mg daily), and the other group included 15 subjects on nebivolol therapy (5 mg daily). After 12 weeks of (-blocker therapy, pravastatin (40 mg daily) was added in both groups for another 12 weeks. Atenolol significantly increased triglyceride levels by 19% (P = .05), while nebivolol showed a trend to increase high-density lipoprotein cholesterol by 8% (NS) and to decrease triglyceride levels by 5% (NS). Atenolol significantly increased lipoprotein(a) by 30% (P = .028). Fibrinogen levels were equally and not significantly decreased in both groups by 9% and 7%, respectively. Furthermore, atenolol and nebivolol decreased serum high-sensitivity C-reactive protein levels by 14% (P = .05) and 15% (P = .05), respectively. On the other hand, both atenolol and nebivolol showed a trend to increase homocysteine levels (NS) by 13% and 11%, respectively. Although uric acid levels remained the same, atenolol significantly increased the fractional excretion of uric acid by 33% (P = .03). Following nebivolol administration, glucose levels remained the same, while insulin levels were reduced by 10% and the HOMA index (fasting glucose levels multiplied by fasting insulin levels and divided by 22.5) was reduced by 20% (P = .05). There were no significant differences between the two patient groups in the measured parameters after the administration of (-blockers, except for triglycerides (P < .05) and the HOMA index (P = .05). The addition of pravastatin to all patients (n = 30) decreased total cholesterol by 21% (P < .001), low-density lipoprotein cholesterol by 28% (P < .001), apolipoprotein-B by 22% (P < .001), apolipoprotein-E by 15% (P = .014) and lipoprotein(a) levels by 12% (P = .023). Moreover, homocysteine levels and C-reactive protein were reduced by 17% (P = .05) and 43% (P = .05), respectively. We conclude that nebivolol seems to be a more appropriate therapy in hypertensive patients with hyperlipidemia and carbohydrate intolerance. Finally, the addition of pravastatin could further correct the well-established predictors of cardiovascular events.

Key Words: atenolol • nebivolol • pravastatin • combination treatment • triglycerides • HOMA • index

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 8, No. 2, 127-134 (2003)
DOI: 10.1177/107424840300800206


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Maffei and G. Lembo Nitric oxide mechanisms of nebivolol Therapeutic Advances in Cardiovascular Disease, August 1, 2009; 3(4): 317 - 327. [Abstract] [PDF]

				J. B. McGill Reexamining Misconceptions About {beta}-Blockers in Patients With Diabetes Clin. Diabetes, January 1, 2009; 27(1): 36 - 46. [Abstract] [Full Text] [PDF]

				L. M. Prisant Nebivolol: Pharmacologic Profile of an Ultraselective, Vasodilatory {beta}1-Blocker J. Clin. Pharmacol., February 1, 2008; 48(2): 225 - 239. [Abstract] [Full Text] [PDF]

				A. Veverka, D. S Nuzum, and J. L Jolly Nebivolol: A Third-Generation {beta}-Adrenergic Blocker Ann. Pharmacother., July 1, 2006; 40(7): 1353 - 1360. [Abstract] [Full Text] [PDF]

				E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF]